IDH1 inhibitor

DRUG CLASS:

IDH1 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	olutasidenib Sensitive: A1 - Approval olutasidenib Sensitive : A1	olutasidenib Sensitive: A1 - Approval olutasidenib Sensitive : A1
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 R132	Acute Myelogenous Leukemia	IDH1 R132	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 mutation	Myelodysplastic Syndrome	IDH1 mutation	Myelodysplastic Syndrome	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH1 R132	Cholangiocarcinoma	IDH1 R132	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
IDH2 mutation	Oligodendroglioma	IDH2 mutation	Oligodendroglioma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH1 mutation	Oligodendroglioma	IDH1 mutation	Oligodendroglioma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH1 mutation	Sarcoma	IDH1 mutation	Sarcoma	ivosidenib Sensitive: A2 - Guideline ivosidenib Sensitive : A2	ivosidenib Sensitive: A2 - Guideline ivosidenib Sensitive : A2
IDH2 mutation	Glioma	IDH2 mutation	Glioma	vorasidenib Sensitive: B - Late Trials vorasidenib Sensitive : B	vorasidenib Sensitive: B - Late Trials vorasidenib Sensitive : B
IDH1 mutation	Glioma	IDH1 mutation	Glioma	vorasidenib Sensitive: B - Late Trials vorasidenib Sensitive : B	vorasidenib Sensitive: B - Late Trials vorasidenib Sensitive : B
IDH1 mutation	Glioma	IDH1 mutation	Glioma	ivosidenib Sensitive: C1 - Off-label ivosidenib Sensitive : C1	ivosidenib Sensitive: C1 - Off-label ivosidenib Sensitive : C1
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C2 – Inclusion Criteria venetoclax + ivosidenib Sensitive : C2	venetoclax + ivosidenib Sensitive: C2 – Inclusion Criteria venetoclax + ivosidenib Sensitive : C2
IDH1 R132C	Cholangiocarcinoma	IDH1 R132C	Cholangiocarcinoma	ivosidenib Sensitive: C2 – Inclusion Criteria ivosidenib Sensitive : C2	ivosidenib Sensitive: C2 – Inclusion Criteria ivosidenib Sensitive : C2
IDH1 R132	Acute Myelogenous Leukemia	IDH1 R132	Acute Myelogenous Leukemia	olutasidenib Sensitive: C2 – Inclusion Criteria olutasidenib Sensitive : C2	olutasidenib Sensitive: C2 – Inclusion Criteria olutasidenib Sensitive : C2
FLT3-ITD mutation + IDH1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + IDH1 mutation	Acute Myelogenous Leukemia	IDH1 inhibitor Sensitive: C3 – Early Trials IDH1 inhibitor Sensitive : C3	IDH1 inhibitor Sensitive: C3 – Early Trials IDH1 inhibitor Sensitive : C3
IDH1 mutation	Glioma	IDH1 mutation	Glioma	BAY1436032 Sensitive: C3 – Early Trials BAY1436032 Sensitive : C3	BAY1436032 Sensitive: C3 – Early Trials BAY1436032 Sensitive : C3
NPM1 mutation + NRAS mutation	Acute Myelogenous Leukemia	NPM1 mutation + NRAS mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
TNFRSF10D expression	Acute Myelogenous Leukemia	TNFRSF10D expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
PTGS2 expression	Acute Myelogenous Leukemia	PTGS2 expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
RNF217-AS1 expression	Acute Myelogenous Leukemia	RNF217-AS1 expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
TFRC expression	Acute Myelogenous Leukemia	TFRC expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
GAS1 expression	Acute Myelogenous Leukemia	GAS1 expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
NAV3 expression	Acute Myelogenous Leukemia	NAV3 expression	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3

IDH1 inhibitor

IDH1 inhibitor

Associations(61)

Associations
(61)